These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23513923)

  • 1. [Challenges and prospects for drug development of molecular targeting agents in Japan].
    Iwasaki M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():695-702. PubMed ID: 23513923
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partnering for therapeutics discovery.
    Colvis CM; Devaney S; Brady LS; Hudson KL
    Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
    [No Abstract]   [Full Text] [Related]  

  • 4. [Application of translational research to drug discovery and development].
    Yamada H
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):121. PubMed ID: 24046885
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug discovery sciences in Japan with focus on molecular-targeted drugs].
    Furukawa K; Hamamura K; Ohkawa Y; Furukawa K
    Nihon Rinsho; 2010 Oct; 68(10):1797-802. PubMed ID: 20954320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug development in Japan from the viewpoints of global pharmaceutical companies].
    Seriu T
    Rinsho Ketsueki; 2009 Jul; 50(7):556-62. PubMed ID: 19638723
    [No Abstract]   [Full Text] [Related]  

  • 7. Importance of fundamental science as the cornerstone for translational research.
    Watson RW
    BJU Int; 2016 Feb; 117(2):205. PubMed ID: 26750492
    [No Abstract]   [Full Text] [Related]  

  • 8. [New perspective for drug discovery and clinical development in kidney disease].
    Miyata T; Kikuchi K; Saito K
    Nihon Jinzo Gakkai Shi; 2012; 54(5):610-4. PubMed ID: 22991841
    [No Abstract]   [Full Text] [Related]  

  • 9. [Research development of novel antineoplastic agents].
    Wada T; Matsui H
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):149. PubMed ID: 24369542
    [No Abstract]   [Full Text] [Related]  

  • 10. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Translational research - towards personalized medicine].
    Tokui T
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):122-5. PubMed ID: 23470475
    [No Abstract]   [Full Text] [Related]  

  • 12. The biomarker is not the end.
    Nohaile M
    Drug Discov Today; 2011 Oct; 16(19-20):878-83. PubMed ID: 21888986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New NIH center broadens scope of translational research.
    Jenks S
    J Natl Cancer Inst; 2012 May; 104(10):728-31. PubMed ID: 22544941
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2017 Jan; 101(1):8-12. PubMed ID: 27869291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 16. [Progress and future of translational research in Japan].
    Ohno T; Nagai Y; Fukushima M
    Nihon Yakurigaku Zasshi; 2010 May; 135(5):190-3. PubMed ID: 20467168
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenges in the Development of Novel Cardiovascular Therapies.
    Hwang TJ; Kesselheim AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):194-196. PubMed ID: 28643861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 19. Anecdotes from ITMAT: building capacity for translational science.
    FitzGerald GA
    Clin Pharmacol Ther; 2013 Sep; 94(3):291-6. PubMed ID: 23963214
    [No Abstract]   [Full Text] [Related]  

  • 20. A new phenotypic lexicon for accelerated translation: rise of the machines.
    MacRae CA
    Circulation; 2015 Jan; 131(3):234-6. PubMed ID: 25601949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.